Questions From the Literature

What is thymosin alpha 1?

Thymosin Alpha-1 (also written Thymosin α1, Tα1, TA-1, or thymalfasin) is a 28-amino-acid polypeptide originally isolated from calf thymus in 1977 ^[7]. It is produced in the body by cleavage from a 113-amino-acid precursor protein called prothymosin alpha, and its N-terminal acetyl group is required for biological activity. The synthetic pharmaceutical form, thymalfasin, is sequence-identical. It acts at the innate-adaptive immune interface — maturing dendritic cells, driving Th1 T-cell responses, and activating a counterbalancing tolerogenic arm through IDO enzyme induction ^[6]. It is approved as a drug in more than 35 countries and has been in clinical use for four decades, primarily for chronic viral hepatitis ^[2].

What does thymosin alpha 1 do?

In broad terms, Thymosin Alpha-1 modulates immune function in two complementary directions. First, it stimulates the immune response: it signals through TLR2 and TLR9 on dendritic cells, promotes their maturation and IL-12 production, and drives Th1 polarization and cytotoxic T-cell activity — the effector side of adaptive immunity ^[6]. Second, it activates a regulatory arm via IDO-mediated tryptophan catabolism that generates regulatory T cells and interleukin-10, providing a counterbalance to unchecked effector activation ^[6]. In practical clinical terms, it has been studied to restore immune competence in immunosuppressed patients — chronic viral hepatitis, post-chemotherapy immunodepression, sepsis-associated immune paralysis — and to enhance responses to vaccines and cancer immunotherapy ^[2][4]. Crucially, the largest sepsis RCT (TESTS, 1,106 adults, 2025) found no significant 28-day mortality benefit ^[1], so its efficacy profile is condition-specific, not universal.

What is thymosin alpha 1 used for?

In approved clinical practice (in the countries where thymalfasin is licensed), Thymosin Alpha-1 is used primarily for chronic hepatitis B and C — where the longest and most consistent human efficacy record exists — and as an immunostimulatory adjuvant in cancer treatment protocols ^[2][4]. Investigational uses include sepsis (where the evidence is mixed; the 2025 TESTS trial was null ^[1]), COVID-19 (retrospective data suggesting T-cell restoration and mortality reduction ^[3]), and immune reconstitution after chemotherapy. In the US, it has no marketing approval; use is investigational or via compounding in limited contexts. This desk summarizes the research record only and does not advise on human use.

Is thymosin alpha 1 FDA-approved?

No. Thymosin Alpha-1 (thymalfasin) is not approved by the FDA for marketing in the United States. It has been investigated under IND applications for specific indications and has received some historical orphan-drug designations, but those are not marketing approvals. In contrast, it is approved as a prescription drug in more than 35 other countries for hepatitis B and C and related immune indications ^[2]. The FDA's 503A bulk-substance review process has evaluated thymosin alpha-1-related substances for compounding and has not endorsed them, reflecting unresolved questions about identity, quality and clinical evidence for compounded US use. Internationally approved use is based on decades of clinical data; US research-grade use operates outside that regulatory framework.

What is thymulin?

Thymulin is a nine-amino-acid thymic hormone — also called serum thymic factor or FTS (facteur thymique serique) — produced exclusively by thymic epithelial cells. Its sequence is pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, and its biological activity is strictly zinc-dependent: the molecule is active only when it carries one bound zinc(II) ion per peptide molecule ^[12]. The zinc-free apo-form is inactive. Thymulin participates in T-lymphocyte differentiation, acts as a hypophysiotropic peptide in the thymus-neuroendocrine axis, and has documented anti-inflammatory properties through NF-kB pathway suppression ^[11]. It has no approved human indication anywhere and is classified as a research peptide.

What is thymulin peptide?

"Thymulin peptide" refers to the same compound described above — the zinc-dependent nonapeptide (Zn-thymulin) produced by the thymus. In the older scientific literature you will find it called FTS (for facteur thymique serique, its French-language original name) or serum thymic factor. A synthetic biologically active analog, sometimes called metFTS or nonathymulin, has been used in gene-therapy research. The compound circulates in blood at very low levels, and its measured serum activity is considered a sensitive index of zinc nutritional status ^[12]. As a research peptide it is distinct from all other thymic compounds: not thymosin alpha-1 (28 amino acids, no zinc requirement), not thymalin (a bovine thymic complex with multiple protein components), not thymosin beta-4, and not thymopentin.

Is thymulin the same as serum thymic factor (FTS)?

Yes — "thymulin" and "serum thymic factor" (FTS) are different names for the same compound. The original French designation was facteur thymique serique, abbreviated FTS; the international name thymulin was adopted later. The zinc-bound complex is sometimes specifically designated Zn-thymulin or FTS-Zn to distinguish the active form from the inactive apo-peptide ^[12]. Some sources also use "nonathymulin" for a particular synthetic analog used in research. When reading older literature, FTS and thymulin can be treated as interchangeable; where a study specifies an analog rather than native thymulin, the text should flag it.

How is thymulin different from thymosin alpha-1?

The two peptides share a thymic origin but are otherwise quite different:

• Structure. Thymosin Alpha-1 is 28 amino acids with an N-terminal acetyl group ^[7]; thymulin is 9 amino acids with a pyroglutamate at one end and a strict zinc requirement ^[12].
• Source. Both come from the thymus, but thymulin is produced exclusively by thymic epithelial cells, while thymosin alpha-1 is a cleavage product of the more broadly distributed prothymosin alpha precursor.
• Zinc dependence. Thymosin Alpha-1 has no zinc requirement. Thymulin is biologically inert without its bound zinc ion.
• Regulatory status. Thymosin Alpha-1 (thymalfasin) is approved in 35+ countries ^[2]; thymulin has no approved indication anywhere ^[11].
• Clinical evidence. Thymosin Alpha-1 has four decades of human RCTs; thymulin's evidence is almost entirely preclinical.
• Mechanism. Thymosin Alpha-1 acts primarily through TLR-mediated dendritic cell maturation and Th1/Treg polarization ^[6]; thymulin acts primarily through T-cell differentiation support and NF-kB anti-inflammatory signaling ^[10][11].

They are not interchangeable in research or clinical contexts.

What was the result of the TESTS sepsis trial?

The TESTS trial (Thymosin Alpha-1 Efficacy and Safety in Sepsis) was a multicentre, double-blind, randomized, placebo-controlled phase-3 trial enrolling 1,106 adults with sepsis across 22 centres ^[1]. It was the largest and most rigorous test of Thymosin Alpha-1 in sepsis to date. The result: 28-day all-cause mortality was 23.4% in the Thymosin Alpha-1 group versus 24.1% for placebo — a hazard ratio of 0.99 (95% CI 0.77-1.27), P=0.93 ^[1]. That is a clearly null result. The earlier ETASS trial (361 patients) had shown a numerically lower mortality (26.0% vs 35.0%) that did not quite reach significance ^[5]; the TESTS result suggests that encouraging signal did not replicate in a definitive test. The null result is important context for anyone reading older, smaller meta-analyses that appeared more positive.

Are thymosin alpha-1 and thymulin the same as thymalin?

No. Thymalin is a separate compound — a bovine thymic complex containing multiple polypeptide components isolated from calf thymus tissue — and it is chemically distinct from both thymosin alpha-1 and thymulin. Thymalin has its own (mostly Soviet-era and Eastern European) clinical literature. Thymulin is a single defined nonapeptide ^[12]; thymosin alpha-1 is a single defined 28-amino-acid peptide ^[7]; thymalin is a heterogeneous extract. The three names are similar, consumer sources conflate them regularly, and they should be treated as distinct entities both in reading the science and in any research context.

Why does the thymus matter for immune function?

The thymus is the organ where T lymphocytes — the adaptive immune system's cytotoxic and helper cells — are educated to distinguish self from non-self. T cells that react too strongly against the body's own tissues are eliminated; those that react usefully against foreign pathogens are matured and released. Thymic peptides like Thymosin Alpha-1 and Thymulin are part of the chemical environment that governs this process ^[6][11]. As the thymus involutes (shrinks) with age — a process that is largely complete by mid-adulthood — circulating thymic peptide levels fall, and so does the output of naive T cells. This is part of the biological rationale for studying thymic peptides as potential strategies for restoring or maintaining immune competence in aging, immunosuppression, or chronic infection settings ^[2]. It also explains why both peptides appear in research on conditions where T-cell function is compromised.